Immatics NV
NASDAQ:IMTX

Watchlist Manager
Immatics NV Logo
Immatics NV
NASDAQ:IMTX
Watchlist
Price: 10.06 USD -0.2%
Market Cap: 1.2B USD
Section:
 

Relative Value

The Relative Value of one IMTX stock under the Base Case scenario is 3.73 USD. Compared to the current market price of 10.06 USD, Immatics NV is Overvalued by 63%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

IMTX Relative Value
Base Case
3.73 USD
Overvaluation 63%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

12.3
P/S
P/S
Price to Sales
12.3
vs History
44
vs Industry
62
Median 3Y
9
Median 5Y
10.9
Industry
7.9
Forward
27.3
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
9
Median 3Y
-9.3
Median 5Y
-7.5
Industry
24
Forward
-5.2
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
1
Median 3Y
-5.3
Median 5Y
-5.9
Industry
21.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
8
Median 3Y
-6.6
Median 5Y
-5.8
Industry
23.7
More Details
2.5
P/B
P/B
Price to Book Value
2.5
vs History
77
vs Industry
50
Median 3Y
2.6
Median 5Y
3.8
Industry
3.4
More Details
7.4
EV/S
EV/S
Enterprise Value to Sales
7.4
vs History
38
vs Industry
77
Median 3Y
4.6
Median 5Y
6.6
Industry
8.3
Forward
16.5
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.3
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
10
Median 3Y
-5
Median 5Y
-5
Industry
6.7
Forward
-3.4
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
9
Median 3Y
-4.6
Median 5Y
-4.6
Industry
7.2
Forward
-3.2
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
2
Median 3Y
-1.5
Median 5Y
-3.7
Industry
8.2
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
9
Median 3Y
-4.1
Median 5Y
-3.8
Industry
6.7
More Details
7.4
EV/IC
EV/IC
Enterprise Value to IC
7.4
vs History
61
vs Industry
55
Median 3Y
7.2
Median 5Y
9.7
Industry
5.7
More Details

Multiples Across Competitors

IMTX Competitors Multiples
Immatics NV Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DE
Immatics NV
NASDAQ:IMTX
1.2B USD 12.3 -9 -4.9 -4.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 924 975 -161 240.4 -195 797.2 -193 563
US
Abbvie Inc
NYSE:ABBV
397.3B USD 6.6 168.9 16.4 23.3
US
Amgen Inc
NASDAQ:AMGN
168.7B USD 4.7 24.2 17.5 17.5
US
Gilead Sciences Inc
NASDAQ:GILD
151.2B USD 5.2 18.6 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.2B USD 9.6 30.6 22.6 23.6
US
Epizyme Inc
F:EPE
94.1B EUR 2 076.6 -529.9 -577 -561.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.2B USD 5.4 16.9 16 18.2
AU
CSL Ltd
ASX:CSL
86.6B AUD 3.7 19.3 13 16.2
NL
argenx SE
XBRU:ARGX
46.2B EUR 15 35.2 60.9 62.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
53.6B USD 16.6 1 224.2 161.6 196
P/S Multiple
Revenue Growth P/S to Growth
DE
Immatics NV
NASDAQ:IMTX
Average P/S: 3 084 284.6
12.3
-28%
N/A
FR
Pharnext SCA
OTC:PNEXF
33 924 975
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.7
5%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.6
10%
1
US
E
Epizyme Inc
F:EPE
2 076.6
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.4
6%
0.9
AU
CSL Ltd
ASX:CSL
3.7
5%
0.7
NL
argenx SE
XBRU:ARGX
15
49%
0.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.6
46%
0.4
P/E Multiple
Earnings Growth PEG
DE
Immatics NV
NASDAQ:IMTX
Average P/E: 192.2
Negative Multiple: -9 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 240.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
168.9
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.2
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.6
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -529.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.9
9%
1.9
AU
CSL Ltd
ASX:CSL
19.3
11%
1.8
NL
argenx SE
XBRU:ARGX
35.2
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 224.2
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DE
Immatics NV
NASDAQ:IMTX
Average EV/EBITDA: 40.1
Negative Multiple: -4.9 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 797.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.4
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.5
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.6
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -577 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16
11%
1.5
AU
CSL Ltd
ASX:CSL
13
8%
1.6
NL
argenx SE
XBRU:ARGX
60.9
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
161.6
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DE
Immatics NV
NASDAQ:IMTX
Average EV/EBIT: 46.2
Negative Multiple: -4.4 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 563 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.3
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.5
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.6
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -561.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.2
13%
1.4
AU
CSL Ltd
ASX:CSL
16.2
11%
1.5
NL
argenx SE
XBRU:ARGX
62.6
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
196
N/A N/A

See Also

Summary
IMTX intrinsic value, competitors valuation, and company profile.
DCF Valuation
IMTX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
IMTX stock valuation using valuation multiples.
Wall Street Estimates
IMTX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
IMTX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 302,300+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.